Patent Application
20220298486
The present invention mainly relates to a urothelial cell induction method. More particularly, it relates to a method for inducing urothelial cells by direct reprogramming, and an agent for converting somatic cells to urothelial cells.
Urothelial cells form urothelium on the surface of the urinary tract that is composed of renal pelvis, ureter, urinary bladder and proximal urethra. The urothelium contracts or expands depending on the amount of urine stored and provides a strong barrier to urine exudation and bacterial invasion. Both or either of loss of urothelial cells and dysfunction are/is associated with urinary tract diseases such as bladder cancer, overactive bladder, congenital bladder anomalies, bladder injury, interstitial cystitis, neurogenic bladder, and contracted bladder. Damaged urothelium in patients could be treated by transplantation of autologous intestine or colon tissue segments (e.g., surgical method of removing intestinal epithelium and transplanting same as bladder epithelium). However, these gastrointestinal tissues easily resorb urine, causing many problems including cancer formation, metabolic acidosis, infection, stone formation, etc.
As current treatments for Hannah-type interstitial cystitis, which is one type of interstitial cystitis, injection of DMSO and xylocaine into the bladder and forcible expansion of the bladder (bladder expansion) are performed. However, although short-term results are good, long-term results are poor, and there is no fundamental treatment method as the situation stands.
In view of such problems, a lot of efforts have been devoted to search for another source of the cells applicable to transplantation instead of gastrointestinal tissue segments. Autologous transplantation of bladder tissue expanded by culture using a collagen-polyglycolic acid scaffold has been reported. This achieved sufficient results for short-terms after the transplantation, but this method has not been widely used because the autologous bladder tissue may become dysfunctional after long-term follow-up. A method for inducing urothelium from non-urothelial immature stem cells has been reported. A method of co-culturing mesenchymal stem cells derived from human fetal bone marrow with urothelial cells of patient (Non Patent Literature 1) and a method of culturing human adipose-derived stem cells by adding culture supernatant of urothelial cells (Non Patent Literature 2) have been reported. However, these cells were hardly applicable to clinical use, because the procedures required autologous urothelial cells. In addition, methods of generating urothelial cells from human ES cells and induced pluripotent stem (iPS) cells have been reported (Non Patent Literatures 3, 4). However, transplantation of cells derived from human pluripotent stem cells could cause teratoma formation.
On the other hand, the direct conversion (direct reprogramming) technology that induces differentiation of tissue cells from another somatic cell lineage without passing through a pluripotent state is known. The present inventors have so far established and reported a direct reprogramming technique from somatic cell (e.g., fibroblast) into osteoblast (Patent Literature 1, Non Patent Literature 5), into brown adipocyte (Patent Literature 2, Non Patent Literature 6), into Schwann cell (Patent Literature 3, Non Patent Literature 7) and into myoblast (Patent Literature 4, Non Patent Literature 8). However, conversion of somatic cells into urothelial cells has not been reported.
The present invention aims to provide a method for generating urothelial cells that can be applied to the treatments of urologic diseases, particularly, diseases caused by urothelial cell damage, diseases caused by loss of urothelial cells and dysfunction, and the like, urothelial cells generated by said method, and a medium for inducing urothelial cells that is suitable for the method.
In view of the above-mentioned problem, the present inventors have conducted intensive studies based on the findings so far. Specifically, they attempted to generate urothelial cells from somatic cells without going through a pluripotent state by direct reprogramming technique. Direct reprogramming can be achieved by transducing genes encoding transcription factors that play an important role in the differentiation stage of target cells and genes that promote reprogramming of somatic cells. The present inventors have found that human fibroblasts can be directly converted into urothelial cells by introducing some genes, established a procedure of the conversion, and analyzed phenotypes and functions of the resultant directly converted urothelial cells (dUC), and completed the present invention.
Accordingly, the present invention provides the following.
[1] A method for introducing a urothelial cell, comprising a step of introducing at least one member selected from the group consisting of
FOXA1 (Forkhead box A1) gene or an expression product thereof,
TP63 (tumor protein P63) gene or an expression product thereof,
MYCL (L-Myc) gene or an expression product thereof, and
KLF4 (Kruppel-like factor 4) gene or an expression product thereof
to a mammalian somatic cell as an exogeneous factor.
[2] The method of the above-mentioned [1], wherein the exogeneous factor comprises FOXA1 gene or an expression product thereof, and TP63 gene or an expression product thereof.
[3] The method of the above-mentioned [1], wherein the exogeneous factor is selected from the following;
(i) KLF4 gene or an expression product thereof
(ii) TP63 gene or an expression product thereof, and KLF4 gene or an expression product thereof
(iii) MYCL gene or an expression product thereof, and KLF4 gene or an expression product thereof
(iv) FOXA1 gene or an expression product thereof, MYCL gene or an expression product thereof, and KLF4 gene or an expression product thereof
(v) TP63 gene or an expression product thereof, MYCL gene or an expression product thereof, and KLF4 gene or an expression product thereof
(vi) FOXA1 gene or an expression product thereof, TP63 gene or an expression product thereof, and KLF4 gene or an expression product thereof
(vii) FOXA1 gene or an expression product thereof, TP63 gene or an expression product thereof, MYCL gene or an expression product thereof, and KLF4 gene or an expression product thereof.
[4] The method of any of the above-mentioned [1] to [3], wherein the aforementioned somatic cell is human fibroblast.
[5] A urothelial cell derived from a mammalian somatic cell and having at least one member selected from the group consisting of
FOXA1 gene or an expression product thereof,
TP63 gene or an expression product thereof,
MYCL gene or an expression product thereof, and
KLF4 gene or an expression product thereof,
as an exogeneous factor.
[6] The cell of the above-mentioned [5], wherein the exogeneous factor comprises FOXA1 gene or an expression product thereof, and TP63 gene or an expression product thereof.
[7] The cell of the above-mentioned [5], wherein the exogeneous factor is selected from the following;
(i) KLF4 gene or an expression product thereof
(ii) TP63 gene or an expression product thereof, and KLF4 gene or an expression product thereof
(iii) MYCL gene or an expression product thereof, and KLF4 gene or an expression product thereof
(iv) FOXA1 gene or an expression product thereof, MYCL gene or an expression product thereof, and KLF4 gene or an expression product thereof
(v) TP63 gene or an expression product thereof, MYCL gene or an expression product thereof, and KLF4 gene or an expression product thereof
(vi) FOXA1 gene or an expression product thereof, TP63 gene or an expression product thereof, and KLF4 gene or an expression product thereof
(vii) FOXA1 gene or an expression product thereof, TP63 gene or an expression product thereof, MYCL gene or an expression product thereof, and KLF4 gene or an expression product thereof.
[8] The cell of any of the above-mentioned [5] to [7], wherein the aforementioned somatic cell is human fibroblast.
[9] An agent for converting a mammalian somatic cell to a urothelial cell, comprising at least one member selected from the group consisting of
FOXA1 gene or an expression product thereof,
TP63 gene or an expression product thereof,
MYCL gene or an expression product thereof, and
KLF4 gene or an expression product thereof,
as an exogeneous factor.
[10] The agent of the above-mentioned [9], wherein the exogeneous factor comprises FOXA1 gene or an expression product thereof, and TP63 gene or an expression product thereof.
[11] The agent of the above-mentioned [9], wherein the exogeneous factor is selected from the following;
(i) KLF4 gene or an expression product thereof
(ii) TP63 gene or an expression product thereof, and KLF4 gene or an expression product thereof
(iii) MYCL gene or an expression product thereof, and KLF4 gene or an expression product thereof
(iv) FOXA1 gene or an expression product thereof, MYCL gene or an expression product thereof, and KLF4 gene or an expression product thereof
(v) TP63 gene or an expression product thereof, MYCL gene or an expression product thereof, and KLF4 gene or an expression product thereof
(vi) FOXA1 gene or an expression product thereof, TP63 gene or an expression product thereof, and KLF4 gene or an expression product thereof
(vii) FOXA1 gene or an expression product thereof, TP63 gene or an expression product thereof, MYCL gene or an expression product thereof, and KLF4 gene or an expression product thereof.
[12] The agent of any of the above-mentioned [9] to [11], wherein the aforementioned somatic cell is human fibroblast.
[13] A vector for converting a mammalian somatic cell to a urothelial cell, comprising at least one member selected from the group consisting of
FOXA1 gene or an expression product thereof,
TP63 gene or an expression product thereof,
MYCL gene or an expression product thereof, and
KLF4 gene or an expression product thereof,
as an exogeneous factor.
[14] The vector of the above-mentioned [13], wherein the exogeneous factor comprises FOXA1 gene or an expression product thereof, and TP63 gene or an expression product thereof.
[15] The vector of the above-mentioned [13], wherein the exogeneous factor is selected from the following;
(i) KLF4 gene or an expression product thereof
(ii) TP63 gene or an expression product thereof, and KLF4 gene or an expression product thereof
(iii) MYCL gene or an expression product thereof, and KLF4 gene or an expression product thereof
(iv) FOXA1 gene or an expression product thereof, MYCL gene or an expression product thereof, and KLF4 gene or an expression product thereof
(v) TP63 gene or an expression product thereof, MYCL gene or an expression product thereof, and KLF4 gene or an expression product thereof
(vi) FOXA1 gene or an expression product thereof, TP63 gene or an expression product thereof, and KLF4 gene or an expression product thereof
(vii) FOXA1 gene or an expression product thereof, TP63 gene or an expression product thereof, MYCL gene or an expression product thereof, and KLF4 gene or an expression product thereof.
[16] The vector of any of the above-mentioned [13] to [15], wherein the aforementioned somatic cell is human fibroblast.
[17] A therapeutic agent for a urologic disease, comprising a cell obtained by the method of any of the above-mentioned [1] to [4], a urothelial cell of any of the above-mentioned [5] to [8], an agent of any of the above-mentioned [9] to [12], or a vector of any of the above-mentioned [13] to [16].
[18] The therapeutic agent of the above-mentioned [17], wherein the urologic disease is a urinary disease.
[19] The therapeutic agent of the above-mentioned [18], wherein the urinary disease is at least one member selected from the group consisting of bladder cancer, overactive bladder, congenital bladder anomalies, bladder injury, interstitial cystitis, neurogenic bladder and contracted bladder.
[20] A medium for urothelial cell induction, comprising 3-isobutyl 1-methylxanthine (IBMX) and epidermal growth factor (EGF).
According to the present invention, urothelial cells can be generating from somatic cells in a short period of time by direct reprogramming. Since the urothelial cells can be easily derived from the somatic cells of the person who receives transplantation, problems such as immunological rejection and the like do not occur when the obtained urothelial cells are transplanted. In addition, since urothelial cells can be directly induced from somatic cells without going through pluripotent states such as iPS cells and ES cells, problems caused by pluripotent stem cells such as canceration and the like can be avoided.
The present invention relates to a method for inducing urothelial cells by converting differentiated somatic cells of a mammal into urothelial cells. “Converting” means converting somatic cells into urothelial cells of interest. One of the preferred embodiments of the method of the present invention is a method for converting somatic cells into urothelial cells without going through a step of reprogramming cells initialization represented by the production of iPS cells, which is also called “direct reprogramming” or “direct conversion”.
Induction to urothelial cells can be performed either in vitro or in vivo.
Urothelial cells (also referred to as transitional epithelial cells) are cells that cover the inside of the urethra from the calyx, renal pelvis, ureter, and bladder to the urethra. In one embodiment, the urothelial cell may be an epithelial cell derived from the bladder.
In the present invention, the somatic cell to be the target of direct reprogramming is not particularly limited, and may be any as long as it is derived from a mammal. When transplanting urothelial cells into a living body, it is preferable to use somatic cells (autologous cells) derived from the subject who receives transplantation in order to reduce the risk of infection, rejection response, and the like. However, depending on the purpose, urothelial cells prepared in advance from somatic cells of another person or another animal can be used for transplantation instead of autologous cells. Alternatively, urothelial cells may be produced from somatic cells of another person or another animal prepared in advance, and used for transplantation. That is, a bank of urothelial cells may be created and used for transplantation purposes. In such cases, MHC can be typed in advance to reduce the risk of rejection response, and the like. In addition, the cell characteristics, tumorigenicity, and the like of urothelial cells can be confirmed in advance.
In the present specification, examples of the mammal include mouse, rat, hamster, human, dog, cat, monkey, rabbit, bovine, horse, swine and the like, particularly human.
As the somatic cells, somatic cells that can be easily collected from a living body can be used. For example, fibroblast, keratinocyte, mouth cavity mucosa epithelial cell, nasal cavity mucosa epithelial cell, airway mucosa epithelial cell, gastric mucosa epithelial cell, intestinal mucosa epithelial cells, vascular endothelial cell, smooth muscle cell (bladder smooth muscle cell, vascular smooth muscle cell, etc.), adipocyte, gingiva cell (gingiva fibroblast, gingiva epithelial cell), pulp cell, periodontal ligament cell, bone marrow cell, bone marrow-derived stromal cell, leukocyte, lymphocyte, conjunctiva epithelial cell, osteoclast and the like, with preference given to fibroblast, keratinocyte, mouth cavity mucosa epithelial cell, gingiva cell, leukocyte, lymphocyte and the like. More preferably, it is a fibroblast. In the present invention, it is preferable to use the above-mentioned cells collected from a living body.
When induction of somatic cells into urothelial cells is performed in vivo, the target somatic cell is preferably a cell present at a site where supply of urothelial cells is desired. For example, when the target disease is interstitial cystitis, the site where the supply of urothelial cells is desired is the inner surface of the bladder, and therefore, the somatic cell to be the starting material is preferably a cell present on the inner surface of the bladder. Examples of the somatic cell to be the starting material include fibroblast, bladder smooth muscle cell, vascular endothelial cell, vascular smooth muscle cell, lymphocyte present in the bladder, and the like.
In the method of the present invention, at least one, preferably two, more preferably three, and even more preferably all four members of FOXA1 (Forkhead box A1) gene or an expression product thereof, TP63 (tumor protein P63) gene or an expression product thereof, MYCL (L-Myc) gene or an expression product thereof, and KLF4 (Kruppel-like factor 4) gene or an expression product thereof is/are introduced as an exogenous factor into somatic cells. As used herein, examples of the “expression product” include mRNAs and proteins of the FOXA1 gene, TP63 gene, MYCL gene and KLF4 gene.
In the method of the present invention, one embodiment of preferable combination of exogeneous factor to be introduced into somatic cells includes a combination of FOXA1 gene or an expression product thereof, and TP63 gene or an expression product thereof.
The method of the present invention wherein the exogeneous factor is selected from the following is also one preferable embodiment.
(i) KLF4 gene or an expression product thereof
(ii) TP63 gene or an expression product thereof, and KLF4 gene or an expression product thereof
(iii) MYCL gene or an expression product thereof, and KLF4 gene or an expression product thereof
(iv) FOXA1 gene or an expression product thereof, MYCL gene or an expression product thereof, and KLF4 gene or an expression product thereof
(v) TP63 gene or an expression product thereof, MYCL gene or an expression product thereof, and KLF4 gene or an expression product thereof
(vi) FOXA1 gene or an expression product thereof, TP63 gene or an expression product thereof, and KLF4 gene or an expression product thereof
(vii) FOXA1 gene or an expression product thereof, TP63 gene or an expression product thereof, MYCL gene or an expression product thereof, and KLF4 gene or an expression product thereof.
All of these can enhance the expression of UPK2 mRNA.
In the method of the present invention, micro RNA, siRNA, shRNA, and DNA expressing them can also be used in addition to the FOXA1 gene or an expression product thereof, TP63 gene or an expression product thereof, MYCL gene or an expression product thereof, and KLF4 gene or an expression product thereof. In addition, various proteins can also be used concurrently.
All of the above-mentioned genes are highly conserved genes in vertebrates. In the present specification, unless the animal name is specifically indicated, the genes including homologs are referred to. Even if the gene has a mutation, including polymorphism, a gene having a function equivalent to that of a wild-type gene product is also included.
For example, the nucleotide sequences of the FOXA1 gene, TP63 gene, MYCL gene and KLF4 gene of humans (Homo sapiens) and the amino acid sequences of the proteins encoded by the nucleotide sequences are registered with the following accession numbers in the GenBank provided by the National Center for Biotechnology Information (NCBI) (when multiple revisions are registered, it is understood to indicate the latest revision):
human FOXA1 gene cDNA sequence: BC_033890, NM_004496 (e.g., BC_033890.1, NM_004496.5),
human FOXA1 protein amino acid sequence: NP_004487 (e.g., NP_004487.2),
human TP63 gene cDNA sequence: BC_039815, NM_003722 (e.g., BC_039815.1, NM003722.5),
human TP63 protein amino acid sequence: NP_003713 (e.g., NP_003713.3),
human MYCL gene cDNA sequence: NM_001033081, NM_001033082, NM_005376 (e.g., NM_001033081.2, NM_001033082.2, NM_005376.4),
human MYCL protein amino acid sequence: NP_001028253.1, NP_001028254.2, NP_005367.2 (e.g., NP_001028253, NP_001028254, NP_005367),
human KLF4 gene cDNA sequence: BC_029923, NM_001314052 (e.g., BC_029923.1, NM_001314052.2),
human KLF4 protein amino acid sequence: NP_001300981 (e.g., NP_001300981.1).
The method of the present invention can be performed according to a known direct reprogramming method except selection of a specific gene, and can be performed, for example, according to the method of any of the following documents:
1: Direct Reprogramming of Fibroblasts into Functional Cardiomyocytes by Defined Factors; Masaki Ieda, Ji-Dong Fu, Paul Delgado-Olguin, Vasanth Vedantham, Yohei Hayashi, Benoit G. Bruneau, and Deepak Srivastava Cell 142: 375-386, 2010.
2: Direct conversion of fibroblasts to functional neurons by defined factors. Thomas Vierbuchen, Austin Ostermeier, Zhiping P. Pang, Yuko Kokubu, Thomas C. Sudhof & Marius Wernig. Nature 46.
3: 1035-1041, 20103: Induction of human neuronal cells by defined transcription factors. Pang Z P, Yang N, Vierbuchen T, Ostermeier A, Fuentes D R, Yang T Q, Citri A, Sebastiano V, Marro S, Sudhof T C, Wernig M. Nature 476: 220-223, 2011.
4: Generation of hyaline cartilaginous tissue from mouse adult dermal fibroblast culture by defined factors Kunihiko Hiramatsu, Satoru Sasagawa, Hidetatsu Outani, Kanako Nakagawa, Hideki Yoshikawa, and Noriyuki Tsumaki, Journal of Clinical Investigation, 121: 640-657, 2011.
5: Induction of functional hepatocyte-like cells from mouse fibroblasts by defined factors. Pengyu Huang, Zhiying He, Shuyi Ji, Huawang Sun, Dao Xiang, Changcheng Liu, Yiping Hu, XinWang & Lijian Hui., Nature 475:386-389, 2011.
6: Direct conversion of mouse fibroblasts to hepatocyte-like cells by defined factors. Sayaka Sekiya & Atsushi Suzuki. Nature 475:390-393, 2011.
7: Direct conversion of human fibroblasts into functional osteoblasts by defined factors. Yamamoto K, Kishida T, Sato Y, Nishioka K, Ejima A, Fujiwara H, Kubo T, Yamamoto T, Kanamura N & Mazda O. Proc Natl Acad Sci USA. 112:6152-6157, 2015.
8: Reprogrammed Functional Brown Adipocytes Ameliorate Insulin Resistance and Dyslipidemia in Diet-Induced Obesity and Type 2 Diabetes. Kishida T, Ejima A, Yamamoto K, Tanaka S, Yamamoto T, Mazda O. Stem Cell Reports. 5: 569-581, 2015.
9: Generation of directly converted human osteoblasts that are free of exogenous gene and xenogenic protein. Yamamoto K., Sato Y., Honjo K., Ichioka H., Oseko F., Sowa Y., Yamamoto T., Kanamura N., Kishida T., Mazda O. J Cell Biochem 117:2538-2545, 2016.
The contents of the above-mentioned documents 1-10 are incorporated herein by reference.
Specifically, it is preferable to incorporate the gene of interest to be an exogenous factor into one or more expression vectors, introduce the expression vector into the target somatic cell, and allow intracellular expression thereof.
A method for introducing the gene includes infecting viral vectors such as retroviral vector, adenoviral vector, lentiviral vector, adeno-associated viral vector, herpes viral vector, Sendai viral vector and the like. In the case of introduction of gene and an expression product thereof, a method for transfecting a plasmid vector, an episomal vector, or a gene expression product (mRNA, protein) with a non-viral vector such as a cationic liposome, a cationic polymer, an electric perforation method, and the like can also be used. In addition, mRNA can also be introduced. All these means used for gene transfer are collectively referred to as a vector in the present specification.
A viral vector is preferable from the aspects of transfer efficiency and stable retention of the transgene, and a plasmid is preferable when the risk of canceration is to be reduced.
In addition, by introducing a gene that serves as a drug selection marker (puromycin resistance, blastsaidin S resistance, neomycin resistance, hygromycin resistance, and the like) together with the gene of interest, and then performing drug selection, the cells expressing the target gene can be selected and then used.
The gene of the present invention may be introduced using a plasmid or a viral vector, for example, a retroviral vector. A viral vector is preferable from the aspects of transfer efficiency and stable retention of the transgene, and a plasmid is preferable when the risk of canceration is to be reduced.
The gene to be introduced into somatic cells can be transcribed by the LTR promoter or may be expressed from another promoter inside the vector. For example, constitutive expression promoters such as CMV promoter, EF-1α promoter, CAG promoter, or the like, or a desired inducible promoter can be utilized. In addition, a chimeric promoter in which a part of the LTR is replaced with other promoter may also be utilized.
When the introduction factor is a gene expression product (e.g., protein), a peptide called Protein Transduction Domain (PTD) or the like is bound to a protein as an expression product and added to the medium to introduce the gene expression product into somatic cells.
In the method of the present invention, differentiated somatic cells of a mammal can be cultured in a medium after introduction of a gene. For example, it is a preferred embodiment when inducing (generating) urothelial cells in vitro.
Culturing can be performed in a suitable container for storing cells and media. As a method for performing suitable culture, a method of culturing under conditions of about 37° C. and a carbon dioxide concentration of about 5% is exemplified, but the method is not limited thereto. Culturing under the above-mentioned conditions can be performed using, for example, a known CO2 incubator.
The period for culturing is not particularly limited as long as the effect of the present invention is not impaired. For example, it can be about 12 hr to 1 month, about 1 day to 3 weeks, or about 3 days to 2 weeks. If necessary, the medium can be exchanged. The culture conditions are preferably those of a conventional method.
In culture, passage can be performed if necessary. When passage is performed, the cells are collected before or immediately after reaching a confluent state and seeded in a fresh medium. In the culture of the present invention, moreover, the medium can also be replaced as appropriate.
A medium to be used in the method of the present invention is not particularly limited. General liquid media such as MEM (Modified Minimum Essential medium), DMEM (Dulbecco's Modified Eagle's medium), EMEM (Eagle's minimal essential medium), αMEM (alpha Modified Minimum Essential medium) and the like can be used. Where necessary, components such as serum components (Fetal Bovine Serum (FBS), Human Serum (HS)), antibiotics such as streptomycin, penicillin and the like, non-essential amino acid (NEAA), and the like can be added.
From the aspect of high efficiency in generating urothelial cells by the method of the present invention, it is preferable to use, as a medium, a differentiation-inducing medium generally used for differentiating urothelial cells. The “differentiation-inducing medium for differentiating urothelial cells” refers to a medium containing a component capable of differentiating pluripotent stem cells (ES cell, iPS cell, and the like) into urothelial cells (hereinafter to be also referred to as the urothelial cell induction medium of the present invention).
As the urothelial cell induction medium, a known medium can be used. For example, the media described in Osborn S. L. et al., Stem Cells Transl Med. 2014; 3(5): 610-619. and Kang M. et al., Int. J. Mol. Sci. 2014, 15(5), 7139-7157 can be used. However, the medium is not limited to these.
Preferably, the urothelial cell induction medium of the present invention contains 3-isobutyl 1-methylxanthine (IBMX) and epidermal growth factor (EGF). The concentration of IBMX in the medium is generally 1 μM-10 mM; however, it is preferable that the medium contains 1 mM-10 mM IBMX for selective maintenance and proliferation of urothelial cells. The concentration of EGF in the medium is generally 0.001-1 ng/mL, preferably 0.01-1 ng/mL. When these components are contained, the conversion from fibroblasts to urothelial cells and subsequent selective maintenance and proliferation of the urothelial cells become more efficient, as shown in the Examples.
One preferred example of the urothelial cell induction medium of the present invention is a medium having the following composition (to be also referred to as “UCM medium” in the present specification).
EpiLife™ medium supplemented with
60 μM calcium,
60 μg/mL bovine brain hypophysis extract,
5 μg/mL human gene recombinant insulin,
gentamicin amphotericin,
0.01 ng/mL human gene recombinant EGF,
1 μM tranylcypromine.
(EpiLife™ medium: medium for culturing keratinocytes)
As a result, urothelial cells are induced from somatic cells. The formation of urothelial cells can be detected by, for example, gene expression of Uroplakin (Uroplakin1b; UPK1), Uroplakin2 (UPK2), CK5, CK17, formation of Asymmetric Unit Membrane, and the like.
The induced urothelial cell contains, as exogeneous factor, at least one, preferably two, more preferably three, and even more preferably all four members selected from the group consisting of FOXA1 gene or an expression product thereof, TP63 gene or an expression product thereof, MYCL gene or an expression product thereof, and KLF4 gene or an expression product thereof. In another embodiment, the exogenous factor contains FOXA1 gene or an expression product thereof, and TP63 gene or an expression product thereof, depending on the type and number of genes to be introduced. In yet another embodiment, it contains the following genes or expression products thereof, or a combination thereof.
(i) KLF4 gene or an expression product thereof
(ii) TP63 gene or an expression product thereof, and KLF4 gene or an expression product thereof
(iii) MYCL gene or an expression product thereof, and KLF4 gene or an expression product thereof
(iv) FOXA1 gene or an expression product thereof, MYCL gene or an expression product thereof, and KLF4 gene or an expression product thereof
(v) TP63 gene or an expression product thereof, MYCL gene or an expression product thereof, and KLF4 gene or an expression product thereof
(vi) FOXA1 gene or an expression product thereof, TP63 gene or an expression product thereof, and KLF4 gene or an expression product thereof
(vii) FOXA1 gene or an expression product thereof, TP63 gene or an expression product thereof, MYCL gene or an expression product thereof, and KLF4 gene or an expression product thereof.
As used herein, “exogeneous” mainly refers to an embodiment of a gene or an expression product thereof introduced as a result of the above-mentioned introduction means, which is different from natural embodiments. For example, a gene whose expression is controlled by a promoter other than natural promoters, a position on a chromosome other than natural ones, an embodiment of a gene existing outside the chromosome, and the like can be mentioned.
Urothelial cells may be obtained as a mixture with cells other than the urothelial cells (e.g., the original somatic cells). In such cases, the urothelial cells and the cells other than the urothelial cells can be separated where necessary. The means for separation is not particularly limited. For example, they can be separated using a cell sorter or magnetic beads.
The urothelial cells induced by the present invention can be preferably used, for example, as a transplant material.
The urothelial cells induced by the present invention can also be used for various studies, technical developments, and the like using urothelial cells. For example, they are useful for basic researches such as analyses of the mechanism of the development, differentiation, and morphogenesis of the urinary organs, and the influence of mechanical stress, nutrition, hormone, and the like on them.
By using the urothelial cell induced by the present invention, urothelial cells can be easily, quickly, and inexpensively established from human and animals having various diseases and genetic backgrounds. Thus, abnormalities of urothelial cells that are related to diseases and genetic backgrounds can be analyzed by biochemical, molecular biological, or immunological methods, and the like, which will be useful for researches such as elucidation of the onset mechanism of diseases and the development of diagnostic methods. Furthermore, the development of medicaments, toxicity test of medicaments, and the like using such urothelial cells are useful for the development of a new therapeutic method for various diseases.
The urothelial cells obtained by the present invention can be used for treating various diseases, particularly urologic diseases. For example, the urothelial cells induced by the present invention can be used in the formation of a substitute bladder in a case of total cystectomy for bladder cancer, the construction of a patch to the site where the urothelium is defective in bladder-vaginal fistula, formation of urothelium for partial supplement in urinary bladder enlargement surgery for cases of bladder fibrosis and atrophy due to neurogenic bladder, urothelial regeneration for severe interstitial cystitis (dysfunction of urothelium), and the like.
Specific diseases to be treated include bladder cancer, overactive bladder, congenital bladder abnormality (e.g., bladder exstrophy, bladder diverticulum, urinary diverticulum abnormality), bladder injury, interstitial cystitis (Hunner type and non-Hunner type), neurogenic bladder, contracted bladder, and the like.
In the present specification, unless otherwise indicated, the term “treatment” is intended to mean an action to be performed while a patient is suffering from a particular disease or disorder, whereby the severity of the disease or disorder, or one or more symptoms thereof are alleviated or the progression of the disease or disorder is delayed or slowed down. In the present specification, the “treatment” includes “prophylaxis”.
The urothelial cells obtained by the present invention can also be used not only for the treatment of diseases but also for the purpose of cosmetology and functional enhancement. The action for humans in that case is also referred to as a treatment in the present specification for convenience, and “patient” can be read as “healthy person” or “human”, and “disease” can be read as “cosmetology” or “function”.
The present invention can also be used for the treatment of diseases of not only humans but also pet animals such as dog, cat, and the like and mammals including domestic animals such as cow, horse, pig, sheep, chicken, and the like. In this case, “patient” is read as “animal patient” or “mammal”.
As described above, urothelial cells can be induced by introducing, as exogeneous factor, at least one, preferably two, more preferably three, and even more preferably all four members selected from the group consisting of FOXA1 gene or an expression product thereof, TP63 gene or an expression product thereof, MYCL gene or an expression product thereof, and KLF4 gene or an expression product thereof into somatic cells, Therefore, the present invention further provides a composition for inducing urothelial cells, containing at least one, preferably two, more preferably three, and even more preferably all four members selected from the group consisting of FOXA1 gene or an expression product thereof, TP63 gene or an expression product thereof, MYCL gene or an expression product thereof, and KLF4 gene or an expression product thereof. The composition for inducing urothelial cells contains a factor used for inducing urothelial cell from somatic cell, and it is desirable that at least one, preferably two, more preferably three, and even more preferably all four members selected from the group consisting of FOXA1 gene or an expression product thereof, TP63 gene or an expression product thereof, MYCL gene or an expression product thereof, and KLF4 gene or an expression product thereof are contained in a form permitting introduction into somatic cells. In another embodiment, the exogenous factor contains FOXA1 gene or an expression product thereof, and TP63 gene or an expression product thereof, depending on the type and number of genes to be introduced. In yet another embodiment, it contains the following genes or expression products thereof, or a combination thereof.
(i) KLF4 gene or an expression product thereof
(ii) TP63 gene or an expression product thereof, and KLF4 gene or an expression product thereof
(iii) MYCL gene or an expression product thereof, and KLF4 gene or an expression product thereof
(iv) FOXA1 gene or an expression product thereof, MYCL gene or an expression product thereof, and KLF4 gene or an expression product thereof
(v) TP63 gene or an expression product thereof, MYCL gene or an expression product thereof, and KLF4 gene or an expression product thereof
(vi) FOXA1 gene or an expression product thereof, TP63 gene or an expression product thereof, and KLF4 gene or an expression product thereof
(vii) FOXA1 gene or an expression product thereof, TP63 gene or an expression product thereof, MYCL gene or an expression product thereof, and KLF4 gene or an expression product thereof.
Specific examples of the form that enables introduction of the above-mentioned genes into somatic cells include a vector incorporating the above-mentioned genes. Here, the above-mentioned genes may be incorporated in different vectors, or two or more kinds of genes may be simultaneously incorporated in one vector.
The type of vector that can be used, and the like are as described above.
The above-mentioned composition can be used, for example, as a medicament (therapeutic drug) in gene therapy.
By introducing at least one, preferably two, more preferably three, and even more preferably all four members selected from the group consisting of FOXA1 gene or an expression product thereof, TP63 gene or an expression product thereof, MYCL gene or an expression product thereof, and KLF4 gene or an expression product thereof into somatic cell (e.g., fibroblast) present at the site where urothelial cell is defective, urothelial cells can be induced at the damaged site by direct reprogramming, thereby contributing to the treatment of urothelial cells and the regeneration of urothelial cells. For introduction of the FOXA1 gene or an expression product thereof, TP63 gene or an expression product thereof, MYCL gene or an expression product thereof, and KLF4 gene or an expression product thereof, the above-mentioned composition of the present invention can be preferably used.
It is understood that the induction method of the present invention includes the above-mentioned in vivo direct reprogramming in addition to in vitro direct reprogramming. Such in vivo direct reprogramming enables, for example, gene therapy to treat various diseases. Specific examples of the disease include those described above.
The in vivo direct reprogramming can be performed according to the direct reprogramming to cardiomyocytes in vivo described in, for example, the following documents except that at least one, preferably two, more preferably three, and even more preferably all four members selected from the group consisting of FOXA1 gene or an expression product thereof, TP63 gene or an expression product thereof, MYCL gene or an expression product thereof, and KLF4 gene or an expression product thereof are introduced into somatic cells (e.g., fibroblast) in the damaged area of urothelial cells.
1: Ieda M. Heart regeneration using reprogramming technology. Proc Jpn Acad Ser B Phys Biol Sci. 2013; 89(3):118-28. Review.
2: Ieda M, Fu J D, Delgado-Olguin P, Vedantham V, Hayashi Y, Bruneau B G, Srivastava D. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell. 2010 Aug. 6; 142(3):375-86.
3: Qian L, Huang Y, Spencer C I, Foley A, Vedantham V, Liu L, Conway S J, Fu J D, Srivastava D. In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature. 2012 May 31; 485(7400):593-8.
In addition, it can also be performed injecting at least one, preferably two, more preferably three, and even more preferably all four members selected from the group consisting of FOXA1 gene or an expression product thereof, TP63 gene or an expression product thereof, MYCL gene or an expression product thereof, and KLF4 gene or an expression product thereof into the lumen such as bladder, renal pelvis, and the like. The above-mentioned gene or an expression product thereof or a combination thereof is injected into the bladder or the renal pelvis with a urethral catheter or the like, and the somatic cells present in the bladder or the renal pelvis are brought into contact with the gene or an expression product thereof or a combination thereof, whereby the somatic cells are induced into urothelial cells.
The contents of the above-mentioned documents 1-3 are incorporated herein by reference.
While Examples are shown in the following, the present invention is not limited to the Examples alone.
aHDF (adult Human Dermal Fibroblast; adult human skin fibroblast)
UC (urothelial cell)
HUC (Human urothelial cell)
dUC (directly converted UC)
FOXA1 (Forkhead box A1; to be also referred to as “F” in the present specification)
TP63 (tumor protein P63; to be also referred to as “T” in the present specification)
MYCL (L-Myc; to be also referred to as “L” in the present specification)
KLF4 (Kruppel-like factor 4; to be also referred to as “K” in the present specification)
IRF1 (Interferon regulatory factor 1; to be also referred to as “I” in the present specification)
GFP (green fluorescent protein)
1. Cell culture
aHDFs were seeded on a laminin-coated 12-well plate or a laminin-uncoated 12-well plate, and the gene was introduced using a retroviral vector. The cells were cultured in CnT-Prime medium or other medium, and 21 days later, observation with a phase contrast microscope, real-time PCR, and analysis of immunocytochemistry were performed. The cells were passaged in fresh culture plates and used for RNA sequencing and penetration assay. In the in vivo experiment, cells into which F, T, L, and K had been introduced were transurethrally transplanted into the injured bladder cavity of an interstitial cystitis mouse through a catheter.
10% FBS (Gibco)-added high-glucose DMEM supplemented with MEM non-essential amino acid, 100 mM sodium pyruvate, and 100 U/mL penicillin-streptomycin was used as “Standard Medium”.
“CnT-Prime (registered trade mark)” medium was purchased from CeLLnTEC.
“Uromedium” medium was produced according to the method of Osborn et al. (Osborn S L, (2014) Stem Cell Transl Med 3(5):610-619.). In summary fashion, the “Uromedium” medium is composed of EpiLife™ medium supplemented with 60 μM calcium (Gibco; MEP1500CA), 60 μg/mL bovine brain hypophysis extract (Gibco), 5 μg/mL human gene recombinant insulin (Diagnocine), 500 ng/mL hydrocortisone (Tokyo Chemical Industry Co., Ltd.), gentamicinamphotericin (Gibco), 2% FBS, 0.1 ng/mL human gene recombinant epidermal growth factor (EGF) (RSD), and 100 μM 3-isobutyl 1-methylxanthine (IBMX) (Sigma-Aldrich).
The “UCM” medium is composed of EpiLife™ medium supplemented with 60 μM calcium, 60 μg/mL bovine brain hypophysis extract, 5 μg/mL human gene recombinant insulin, gentamicinamphotericin, 2% FBS, 0.01 ng/mL human gene recombinant EGF, 1 mM IBMX, and 1 μM tranylcypromine (Abcam).
aHDFs and Plat-GP cells were purchased from ScienCell Research Laboratories and Cell Biolabs, respectively, and cultured in Standard Medium. aHDFs at passage number of not more than 10 were used for experiments. HUCs were purchased from KURABO INDUSTRIES LTD. (KP-4309; Lot04101). Induced pluripotent stem cells (iPS cells) were purchased from JCRB cell Bank, and maintained according to the previous report (Nakagawa M, et al., (2014) Sci Rep
4(3594):10.1038/srep03594.1). In summary fashion, iPS cells were cultured on a plate coated with Easy iMatrix-511 silk (Nippi, Incorporated; 0.25 μg/cm2; treated in advance at 37° C. for 1 hr) in a StemFit medium (Ajinomoto Co., Inc.; AK02N). For passage, iPS cells were dissociated into a single cell suspension in StemFit medium containing Rock inhibitor (Nacalai Tesque; Y-27632), and reseeded in new culture plates. The next day, the medium was replaced with fresh StemFit medium without Rock inhibitor, and the medium was changed every other day. Passage was performed when iPS cells reached 80% to 90% confluency. T24, human bladder carcinoma cell line, was provided by professor Ashihara (Kyoto Pharmaceutical University, Kyoto, Japan), and cultured in RPMI1640 medium supplemented with 10% FBS, MEM non-essential amino acid, 100 mM sodium pyruvate and 100 U/mL penicillin-streptomycin.
As primary antibodies for immune antibody staining, rabbit polyclonal anti-uroplakin 1b IgG (Abcam; #ab102961; dilution 1:100), rabbit polyclonal anti-uroplakin 2 IgG (Proteintech; #21149-1-AP; 1:100), mouse monoclonal anti-E-cadherin IgG (BD Biosciences; #610181; 1:50), rabbit polyclonal anti-Nanog IgG (Reprocell; #09-0020; 1:200), and mouse monoclonal anti-keratin 8/18 IgG (CST Japan; #4546S; 1:50), and rabbit monoclonal anti-keratin 20 IgG (CST Japan; #13063; 1:100) antibodies were used. As secondary antibodies, the following antibodies were used. goat Alexa Fluor 488-conjugated anti-rabbit IgG and anti-mouse IgG antibodies (Life technologies; #A11034 and #11029; 1:500), and goat Alexa Fluor 594-conjugated anti-rabbit IgG and anti-mouse IgG antibodies (Life technologies; #A11037 and #11032; 1:500).
Full length cDNA clones for FOXA1, IRF1, TP63, and Sonic hedgehog genes were purchased from DNAFORM library, and coding sequences were amplified by RT-PCR with KOD-Plus-Neo DNA polymerase (TOYOBO CO., LTD.). The primer sequences were as follows.
The amplified DNA fragments were cloned into PMxs retroviral plasmid vector (Cell Biolabs) using the Gene Art System (Invitrogen). pMxs plasmids containing human POU5F1, KLF4, MYCL, GFP genes were provided by professor Yamanaka (CiRA, Kyoto University, Kyoto, Japan). Plat-GP cells were seeded in 100 mm plates at a density of 3×106 cells/dish and cultured for 24 hr. The aforementioned 5.0 μg of pMxs and 2.5 μg of pCMV-VSV-G were introduced into the cells by using XtremeGENE 9 DNA Transfection Reagent (Sigma-Aldrich). After 24 hours the medium was replaced with antibiotic-free Standard Medium. The supernatant of the culture medium was cultured and used as a retroviral suspension.
6. Conversion of Fibroblasts into dUCs
aHDFs were seeded in 12-well plates coated with atelocollagen (KOKEN; I-PC30), poly-L-lysine (ScienCell), or laminin (Easy iMatrix-511 silk) at a density of 3×104 cells/well. After 24 hr, the medium was replaced with the retroviral suspension that was filtrated through a 0.45 μm pore filter (Toyo Roshi Kaisha, Ltd., ADVANTEC) and supplemented with 4 μg/mL polybrene. The next day, the culture supernatant was replaced with Standard Medium free of virus, and replaced with CnT-Prime or “UCM” medium 3 days later. The culture medium was changed every 3 or 4 days.
7. Passages of dUCs
dUCs were passaged when they reached 60 to 80% confluency or 14 days after the previous passage. dUCs were detached using trypsin/EDTA (Nacalai Tesque) and Cell Scraper (IWAKI), reseeded in laminin-coated 12-well plates at a density of 1×104 cells/well, and cultured in “UCM” medium.
8. Differentiation Induction of iPS Cell into Urothelial Cell
iPS cells were converted to urothelial cells by the method of the previous report (Osborn S L, et al., (2014) Stem Cell Transl Med 3(5):610-619.) after slight modification. In summary fashion, iPS cells were seeded in laminin-coated 6-well plates at a density of 2×104 cells/well and cultured until they reached 60 to 70% confluency. The medium was replaced with RPMI1640 supplemented with 2% FBS, GlutaMAX (Gibco), 100 U/mL penicillin-streptomycin, and 5 μM IDE1 (Cayman). The medium was replaced with a fresh one every 1-2 days. Nine days after differentiation induction into definitive endoderm (DE) cells, the medium was replaced with “Uromedium” to allow differentiation of the DE cells into urothelial cells. The medium was changed every 2-3 days during the 18 day culture period, and the cells were cultured in a medium containing 10 mM Rosiglitazone (Sigma-Aldrich) and not containing EGF for 3 days.
Total RNA was extracted using RNeasy Mini Kit (Qigen) according to the manufacturer's protocol. Total RNA of human urothelial cell (HUC) was purchased from ScienCell Research Laboratories (#4325, Lot 4740). Total RNAs of human small intestine, liver were purchased from Clontech Laboratories (#636539, Lot 1611206A; #636531, Lot 1703002). Total RNA of human salivary gland was purchased from BioChain (R1234212-10, Lot B111155). Total RNA of endothelial cell was extracted from human umbilical vein endothelial cell (HUVEC; PromoCell; C-12200). cDNA was synthesized using ReverTra Ace qPCR (TOYOBO Life Science), and subjected to real-time RT-PCR using StepOnePlus Real-Time PCR Systems (Applied Biosystems). The reaction mixture included Taqman probe (Applied Biosystems) and Taqman Fast Advanced Master Mix (Applied Biosystems). The relative mRNA expression levels were calculated from the following formula:
Relative mRNA level (fold)=[(target gene mRNA level in sample/β-actin gene mRNA level in sample)]/[(target gene mRNA level in control sample)/(β-actin gene mRNA level in control sample)].
Cells cultured in 12-well plates were washed with PBS(−), fixed with 4% paraformaldehyde (PFA) for 30 min, and subjected to a membrane permeation treatment using 0.2% Triton-X 100 (Nacalai Tesque) at room temperature for 15 min. Background was blocked by adding Blocking One Histo (Nacalai Tesque) for 30 min at room temperature, and the cells were reacted with a primary antibody overnight at 4° C. After washing, secondary antibodies were added and the cells were reacted for 1 h at room temperature in the dark. The cells were washed and cell nuclei were stained with Hoechst 33342 (DOJINDO) for 5 min. The cells were observed by BZ-X (Keyence). Positive or negative cells for each signal were counted by BZ-X Analyzer software (Keyence). The percentage of signal-positive cells was calculated from the following formula.
% of signal positive cell=(signal positive and Hoechst positive cells/total number of Hoechst 33342 positive cells)×100
Total RNA was extracted from aHDFs and P2 dUCs (cultured in UCM) with the RNeasy Mini Kit (QIAGEN) according to the manufacturer's protocol. Total RNA from human urothelial cells (HUCs) was purchased from ScienCell Research Laboratories. The quality of each RNA sample was checked by agarose gel electrophoresis (gel concentration: 1%, voltage: 180 V, electrophoresis time: 16 min) and Agilent 2100 analysis. Library preparation and sequencing were performed by Novogen Inc. Briefly, ribosome RNA was removed using the Ribo-Zero kit. The mRNA was randomly fragmented by adding a fragmentation buffer, and cDNA was synthesized. The quality-checked libraries were sequenced with Illumina Novaseq 6000 (Illumina; paired-end, 150 bp). Filtered sequence data were mapped on Reference genome (GRCh38) using HISAT2 version 2.1.0 (https://ccb.jhu.edu/software/hisat2/index.shtml). After removing residual ribosome RNA from the sequence results identified by Bedtools (https://bedtools.readthedocs.io/en/latest/), the mapped sequences were counted using featurecounts (http://bioinf.wehi.edu.au/featureCounts/) (Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923-930 (2014)), and associated with the annotation GTF file from GENCODE (GENCODE 29; https://www.gencodegenes.org/). Analysis was performed using iDEP8.1 (Ge, S. X., Son, E. W. & Yao, R. iDEP: an integrated web application for differential expression and pathway analysis of RNA-Seq data. BMC Bioinformatics 19, 10.1186/s12859-018-2486-6 (2018)). The read count data were normalized by CPM (counts per million) function in edgeR, and the genes that did not have not less than 0.5 counts/million in at least one sample were eliminated. Converted data were used for search analysis (hierarchical clustering analysis and gene expression variation analysis), and non-converted data were used for pathway analysis by GSEA (Gene Set Enrichment Analysis) as fold-change values returned by DESeq2. The gene expression data was visualized on KEGG pathway diagrams (Kanehisa, M., Furumichi, M., Tanabe, M., Sato, Y. & Morishima, K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res 45, D353-D361 (2017)) using Pathview (Luo, W. & Brouwer, C. Pathview: an R/Bioconductor package for pathway-based data integration and visualization. Bioinformatics 29, 1830-1831 (2013)).
HTS Transwell clear 12-well plates were purchased from Corning Incorporated, and the inner chambers thereof, which contained polycarbonate membrane with a diameter of 12 mm with 0.4 μm pores, were coated with Easy iMatrix-511 silk (Nippi, Incorporated; 0.25 μg/cm2, preincubated at 37° C. for 1 hr). P4 dUCs or aHDFs were resuspended in UCM medium and seeded in the inner chamber at a density of 1×105 cells/well. HUCs were resuspended in Urolife™ D Complete Medium (Urolife) and seeded in the inner chamber at a density of 1×105 cells/well. For final differentiation, a part of HUCs were cultured in Urolife added with 1 μM Rosiglitazone (PPARy activator; Sigma-Aldrich) and 1 μM PD153035 (EGFR inhibitor; TCI) for 4 days. The cells were cultured for 5 days and then washed with PBS(−). FITC-labeled dextran with a molecular weight of about 4 kDa (IWAI CHEMICALS COMPANY LTD.) was added into the inner chamber at a concentration of 2 mg/mL. After culturing incubation for 20 min under shading, the supernatant in the outer chamber was transferred into 96-well plates, and fluorescence intensity in each well was measured by SpectraMax M2 (Molecular Devices) with fluorescence 533 nm, excitation 485 nm. The relative value (%) of the FITC-labeled dextran leaked into the outer chamber to that of the control without seeding of cells as 100% was calculated by the following formula:
%=(fluorescence intensity in each well/fluorescence intensity without addition of FITC-labeled dextran)/(fluorescence intensity in control well/fluorescence intensity without addition of FITC-labeled dextran)×100
13. Transplantation of dUCs into Mouse Bladder
All animal experiments were approved by the Committee for Animal Experiments of the university (M30-281). The handling of the animals was in accordance with the guideline of the university. Female NOG/BALB-Rag2nullIL-2Rynull/NSG (NOG/SCID) (NOG/SCID) mice were purchased from CLEA Japan, Inc. An interstitial cystitis model of mice and intra-bladder cell transplantation method were as in the previous report (Homan T, et al., (2013) J Pharmacol Sci 121(4):327-337., Shimizu T, et al., (2018) Oncoimmunology 7(5):e1424671.) with slight modifications. 6- to 8-week-old mice under anesthesia were intraperitoneally injected with anti-asialo GM1 antibody at a dose of 100 mg/mouse. At the same time, a 24-gauge catheter was inserted into the bladder through the urethra, and 50 μL of 1.5% H2O2 solution was injected into the bladder. One hour later, the bladder was washed with PBS(−), and a solution containing 50 μL of 12,000 PU dispase II (FUJIFILM Wako Pure Chemical Corporation) was injected into the bladder, and Easy iMatrix 511 silk was administered for 1 hr. aHDFs with introduction of F, T, L, and K thereinto were cultured in Standard Medium for 4 days, suspended in PBS(−) at a concentration of 3×106/100 μL, and transplanted into the bladder (n=4 each). In other groups, aHDFs (3×106 cells/100 μL PBS) free of gene introduction or PBS(−) alone was injected into the bladder. The urethra was sutured, and the suture was removed 3 hr later to allow spontaneous urination.
6- to 8-week-old female NOG/SCID mice were anesthetized and 100 mg of anti-asialo GM1 antibody was intraperitoneally injected. aHDFs with introduction of F, T, L, and K thereinto were cultured in Standard Medium for 4 days, mixed with Matrigel (Corning), and subcutaneously administered to the mice at a concentration of 1×107/100 μL. T24 cells and aHDFs free of gene introduction were used as a positive control and negative control, respectively. The diameter of the tissue swelling at the administration site, or when a tumor was formed, the diameter of the tumor was measured with a caliper every week for 10 weeks, and the volume was calculated.
The bladder was removed from the mice 7 days after the cell transplantation. After fixation in formaldehyde, in some organs, it was substituted with 30% sucrose/PBS(−). Other parts were embedded in paraffin. Samples were sliced into 5-10 thickness. After blocking the endogenous peroxidase activity with 3% H2O2 for 5 min, they were incubated with Protein Block (Dako) for 30 min. After washing, tissue sections were reacted with primary antibodies overnight at 4° C. The tissues were washed and reacted with Alexa Fluor 594-labeled goat anti-rabbit IgG or anti-mouse IgG secondary antibodies for 60 min at room temperature. After washing 3 times, tissue sections were encapsulate using VECTASHIELD mounting medium containing DAPI (Vector Laboratories). Fluorescence was observed using BZ-X (Keyence).
Each data is expressed in mean±SD. Statistical significance was tested by Student's t-test or one-way ANOVA and post hoc Tukey-Kramer test. The statistically significant difference was set at P<0.05. All analyzes were performed using EZR (Kanda, Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone. Marrow. Transplant. 48, 452-458 (2013)).
Adult Human Skin Fibroblasts (aHDFs) were Induced to Express Urothelial Cell-Like Phenotype by Introducing Specific Factor.
First, three transcription factors were focused on. FOXA1(F) and IRF1(I) are important in the development of urothelial cells. On the other hand, TP63 (T) is a transcription factor that is expressed in epithelial stem cells and is associated with the development and differentiation of urothelial cells. In addition, sonic hedgehog (SHH) gene (H), which is expressed in the basement membrane cells of urothelial cells and regulates signals important for cell proliferation during the regeneration process, was added. These genes were introduced into adult human skin fibroblasts (aHDFs) using a retroviral vector and the cells were cultured in CnT-Prime medium for a period considered to be suitable for cell maintenance (21 days) (
Whether F, T, L, and K are necessary and sufficient for inducing the expression of UPK1b and UPK2 was verified. The mRNA expression level of UPK1b increased in cells converted with F, L, and K, and the mRNA expression level of UPK2 was very high in the combination of T, L, and K. The combination of L and K and the combination of F, L, and K also significantly increased the mRNA expression level of UPK2. The combination of F, T, L, and K induced increased mRNA expression in both UPK1b and UPK2 (
How the coating of the culture plates affects the efficiency of cell conversion was examined. Before seeding aHDFs, the culture plates were coated with collagen, poly-L-lysine, or laminin. Epithelial cell colonies were formed only in laminin-coated plates (
Cells with or without introduction of F, T, L, and K thereinto were cultured in various media. As shown in
Characteristics of Directly-Converted Urothelial Cells (dUCs).
The cells transduced by the method of Example 1 are indicated as directly-converted urothelial cells (dUC). Then, the detailed characteristics of the cells were investigated. In the time-course analysis, cells transduced by F, T, L, and K markedly expressed UPK1b 8 days after gene introduction, and the expression peaked 15 days later (
In addition to the expression of UPK1b and UPK2, the expression of E-cadherin, which is a transmembrane type protein expressed in general epithelial cells, and keratin 8/18, which is a cytoskeleton, was confirmed. Immunocytochemical analysis revealed that about 42% of the cells expressed UPK1b, whereas 23%, 26%, and 26% of UPK2-positive, E-cadherin-positive, and keratin 8/12-positive cells respectively expressed UPK1b (
Osborn et al. reported a method for differentiating iPS cells into urothelial cells via endoderm (Osborn S L, et al., (2014) Stem Cell Transl Med 3(5):610-619.). Therefore, dUCs prepared by direct conversion were compared with iPS cell-derived urothelial cells (iUCs) induced by the method of Osborne et al. after slight modification (
Pluripotency, Liver, Small Intestine Markers were not Expressed in dUCs.
To exclude the possibility that fibroblasts were temporarily converted to iPS cells or endodermal progenitor cells that subsequently produced urothelial cells, expression of pluripotent markers and non-urothelial endodermal markers, and the expression of non-urothelial endodermal markers in cells into which F, T, L, and K were introduced during the conversion process were examined. As a result, gene expressions of NANOG, POU5F1, LIN28, and SOX2 were not observed during the culture period in cells into which F, T, L, and K were introduced. NANOG protein was not observed, either (
dUCs can be Selectively Proliferated by Passage Culture.
The dUC colonies formed in 21 days after gene introduction did not grow actively even when continuously cultured on the same medium. To secure a large amount of dUCs with high purity, cell culture was started in the first medium (generation number 0, P0) and then passaged in a new medium (generation number 1, P1). However, when P0 dUCs prepared in the CnT-Prime medium were newly cultured in the same medium, almost no epithelial cell colonies were formed, and only a few non-epithelial cells proliferated. The “Uromedium” did not form a pavingstone-like colony even in the next generation (
Based on these results, the most suitable composition of m culture medium for the passage of dUCs was determined. This medium named urothelial cell conversion maintenance medium (UCM) has the following composition.
EpiLife™ medium supplemented with
60 μM calcium,
60 μg/mL bovine brain hypophysis extract,
5 μg/mL human gene recombinant insulin,
30 μg/mL gentamicin,
15 ng/mL amphotericin,
0.01 ng/mL human gene recombinant EGF,
1 μM tranylcypromine.
UCM supported epithelial cell colony formation of cells into which F, L, T, and K were introduced and suppressed the growth of fibroblast-like cells (
dUCs Exhibit Remarkable Barrier Function In Vitro.
Then, the barrier function of P4 dUCs was checked using an in vitro permeability assay using a transwell. P4 dUCs were cultured to confluence on the bottom membrane of a laminin-coated inner chamber (
RNA Sequence Further Confirmed Characteristics of P2 dUCs as Urothelial Cells.
Similarity between P2 dUCs and urothelial cells was analyzed by RNA sequencing. Gene expression profiling analysis by hierarchical clustering of full-length genome clarified that dUCs were more similar to HUCs than to aHDFs (
dUCs May Contribute to Regeneration of Damaged Urothelial Cell In Vivo.
Whether aHDFs into which F, T, L, and K were introduced are converted to dUCs in vivo and contribute to regeneration of urothelial cell was examined. aHDFs into which F, T, L, K and GFP genes had been introduced were converted to GFP-labeled dUCs when they were cultured in CnT-Prime medium for 21 days (
Study of Presence or Absence of Tumorigenicity of dUCs
The potential tumorigenicity of dUCs was investigated. In the previous tests, aHDFs into which F, L, T, and K had been introduced did not form tumor even after subcutaneous inoculation to immunodeficient mice (
In the same manner as in Example 1, it was confirmed that the urothelial cell-like phenotype was expressed by introducing a specific factor into aHDFs. The results are shown in
According to the present invention, urothelial cells can be prepared from somatic cells in a short period of time by direct reprogramming. Since the urothelial cells can be easily derived from the somatic cells of the person who receives transplantation, problems such as immunological rejection and the like do not occur when the obtained urothelial cells are transplanted. In addition, since urothelial cells can be directly induced from somatic cells without going through iPS cells and ES cells, problems caused by pluripotent stem cells such as canceration and the like can be avoided.
This application is based on a patent application No. 2019-159070 filed in Japan (filing date: Aug. 30, 2019), the contents of which are incorporated in full herein.
| Number | Date | Country | Kind |
|---|---|---|---|
| 2019-159070 | Aug 2019 | JP | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/JP2020/032644 | 8/28/2020 | WO |
